Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

The employee awards carry a $82.25 exercise price and vest over an initial anniversary milestone followed by monthly installments.

Rhea-AI Summary

Dianthus Therapeutics (DNTH) granted stock options covering 26,000 common shares to three newly hired, non-executive employees as employment inducements.

The options have an exercise price of $82.25 per share and a 10-year term. They vest 25% on the first anniversary of the vesting commencement date, followed by equal monthly installments over 36 months. The independent Compensation Committee approved the awards under Nasdaq Listing Rule 5635(c)(4). The grants are subject to the Equity Inducement Plan and a stock option agreement.

Positive

• None.

Negative

• Minor point. Forward-looking: it has not happened yet and may not happen.Options covering 26,000 common shares at $82.25 per share create potential dilution upon exercise.

Key Figures

Aggregate option shares: 26,000 shares Exercise price: $82.25 per share Option term: 10 years +3 more

Aggregate option shares

26,000 shares

Non-qualified stock options granted to three newly hired employees

Exercise price

$82.25 per share

Inducement options

Option term

10 years

Inducement options

Initial vesting

25%

On the first anniversary of the vesting commencement date

Subsequent vesting period

36 months

Equal monthly installments after initial vesting

Newly hired employees

3 employees

Non-executive employees receiving inducement grants

Key Terms

inducement grants, non-qualified stock options, nasdaq listing rule 5635(c)(4)

3 terms

inducement grants financial

"The inducement grants were approved by the Company's independent Compensation Committee"

Inducement grants are special awards of shares or stock options given to new employees to encourage them to join a company or accept a new role. They act like a welcome bonus, providing an extra incentive to attract talent. For investors, these grants can impact a company's costs and share structure, influencing the value of their investments.

non-qualified stock options financial

"The inducement grants consist of non-qualified stock options to purchase an aggregate"

Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK and WALTHAM, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced that it granted equity awards on November 2, 2026, to three newly-hired, non-executive employees. The inducement grants were approved by the Company's independent Compensation Committee and were made as material inducements to acceptance of employment with Dianthus in accordance with Nasdaq Listing Rule 5635(c)(4).

The inducement grants consist of non-qualified stock options to purchase an aggregate of 26,000 shares of the Company's common stock with a 10-year term and an exercise price of $82.25 per share. The options vest as to 25% on the first anniversary of the vesting commencement date and in equal monthly installments for the following 36 months. The inducement grants are subject to the terms and conditions of the Dianthus Therapeutics, Inc. Equity Inducement Plan, and the terms and conditions of a stock option agreement.

About Dianthus Therapeutics
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases. Based in New York City and Waltham, Mass., Dianthus is comprised of an experienced team of biotech and pharma executives who aim to deliver transformative medicines for people living with severe autoimmune and inflammatory diseases.

To learn more, please visit www.dianthustx.com and follow us on LinkedIn. 

Contact
Jennifer Davis Ruff
Dianthus Therapeutics
jdavisruff@dianthustx.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What employee inducement grants did Dianthus Therapeutics announce?

Dianthus granted three newly hired, non-executive employees non-qualified stock options covering 26,000 common shares, with an exercise price of $82.25 per share and a 10-year term.

How do Dianthus Therapeutics' employee inducement options vest?

The options vest 25% on the first anniversary of the vesting commencement date, then in equal monthly installments over the following 36 months. The grants are subject to the Equity Inducement Plan and a stock option agreement.